GoodRx Holdings, Inc. (NASDAQ:GDRX - Get Free Report) shares gapped down prior to trading on Thursday . The stock had previously closed at $7.61, but opened at $7.10. GoodRx shares last traded at $7.19, with a volume of 492,857 shares traded.
Analyst Ratings Changes
A number of research firms recently commented on GDRX. SVB Leerink began coverage on GoodRx in a report on Monday, February 26th. They issued an "outperform" rating and a $8.00 price objective on the stock. TD Cowen lifted their price objective on GoodRx from $12.00 to $14.00 and gave the company an "outperform" rating in a research report on Friday, March 1st. Leerink Partnrs reissued an "outperform" rating on shares of GoodRx in a research note on Monday, February 26th. UBS Group upped their target price on shares of GoodRx from $5.00 to $8.00 and gave the company a "neutral" rating in a research report on Friday, March 1st. Finally, The Goldman Sachs Group upped their price objective on GoodRx from $6.50 to $7.50 and gave the company a "neutral" rating in a report on Friday, March 1st. One analyst has rated the stock with a sell rating, eight have given a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $8.78.
Check Out Our Latest Research Report on GDRX
GoodRx Stock Down 8.9 %
The company has a debt-to-equity ratio of 0.85, a current ratio of 7.12 and a quick ratio of 7.12. The firm's 50 day moving average is $7.05 and its two-hundred day moving average is $6.38. The firm has a market capitalization of $2.74 billion, a P/E ratio of -346.33, a PEG ratio of 3.89 and a beta of 1.37.
GoodRx (NASDAQ:GDRX - Get Free Report) last released its quarterly earnings data on Thursday, February 29th. The company reported $0.02 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.02. The firm had revenue of $196.64 million for the quarter, compared to analyst estimates of $195.59 million. GoodRx had a positive return on equity of 2.45% and a negative net margin of 1.18%. Research analysts predict that GoodRx Holdings, Inc. will post 0.23 EPS for the current year.
Institutional Investors Weigh In On GoodRx
A number of institutional investors have recently modified their holdings of GDRX. Vanguard Group Inc. grew its position in shares of GoodRx by 2.1% during the 3rd quarter. Vanguard Group Inc. now owns 8,681,111 shares of the company's stock worth $48,875,000 after purchasing an additional 177,961 shares in the last quarter. Rubric Capital Management LP bought a new stake in GoodRx during the fourth quarter worth about $39,348,000. Rip Road Capital Partners LP grew its stake in GoodRx by 25.8% during the fourth quarter. Rip Road Capital Partners LP now owns 1,763,277 shares of the company's stock worth $11,814,000 after buying an additional 361,294 shares in the last quarter. Fuller & Thaler Asset Management Inc. acquired a new stake in shares of GoodRx in the 3rd quarter valued at $8,866,000. Finally, Assenagon Asset Management S.A. raised its stake in GoodRx by 7.9% during the fourth quarter. Assenagon Asset Management S.A. now owns 1,349,800 shares of the company's stock worth $9,044,000 after acquiring an additional 99,072 shares in the last quarter. Institutional investors own 63.77% of the company's stock.
GoodRx Company Profile
(
Get Free Report)
GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.
Read More
Before you consider GoodRx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GoodRx wasn't on the list.
While GoodRx currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
